Antibody Drug Conjugate - Competitive landscape, 2025

DelveInsight’s, “Antibody Drug Conjugate - Competitive landscape, 2025” report provides comprehensive insights about 180+ companies and 290+ drugs in Antibody Drug Conjugate Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Antibody Drug Conjugate: Understanding

Antibody Drug Conjugate: Overview

The emergency of mAbs has changed the paradigm of cancer therapy through precise targeting of tumor surface antigens, however, treatment using mAbs alone is often insufficient, potentially due to less satisfactory lethality against cancer cells compared to chemotherapy. Hence, a novel concept, known as antibody–drug conjugate (ADC), was conceived to bridge the gap between the mAb and cytotoxic drugs for the improvement of the therapeutic window. ADC consists of tumor-targeting mAbs conjugated to a cytotoxic payload through a sophisticatedly designed chemical linker, enabling the ability of precise targeting and potent effectiveness simultaneously. Moreover, owing to the conjugation of a large hydrophilic antibody, the antigen-independent uptake of cytotoxic payload in those antigen-negative cells is limited, contributing to a widening therapeutic index.

ADC is composed of antibody, cytotoxic payload, and chemical linker. An ideal ADC drug remains stable in blood circulation, reaches the therapeutic target accurately, and eventually releases the cytotoxic payloads in the vicinity of the targets (e.g. cancer cells). Each element can affect the final efficacy and safety of ADC, and in general ADC development needs to take into account all these key components, including the selection of target antigen, antibody, cytotoxic payload, linker, as well as conjugation methods. ADCs synergistically play the “specific” targeting role and the “efficient” killing effect on cancer cells. Such drugs are like a precision-guided “biological missile” with the ability to destroy cancer cells accurately, improving the therapeutic window and reducing the off-targeted side effects. Once mAb of ADC is bound to the target antigens that are specifically expressed on the cancer cells, the ADC is endocytosed/internalized by cells to form an early endosome, followed by a maturation into late endosomes and finally fused with lysosomes.

The cytotoxic payloads are eventually via either chemical or enzyme-mediated release in the lysosomes, resulting in cell apoptosis or death via targeting DNA or microtubules. When the payload released is permeable or trans-membrane, it may also induce a bystander effect to enhance the efficacy of ADC. Moreover, the bystander effect of these drugs may also alter the tumor microenvironment, which in turn may further enhance the killing effect of ADCs. In addition, the anticancer activity of ADC is also involved in the ADCC, ADCP, and CDC effects. The Fab segment of antibodies of some ADCs could bind to the antigen epitope of virus-infected cells or tumor cells while the FC segment binds to FCR on the surface of killer cells (NK cells, macrophages, etc.), thereby mediating the direct killing effects. Furthermore, the antibody component of ADC could specifically bind to the epitope antigen of cancer cells and inhibits the downstream signal transduction of antigen receptor. For example, the trastuzumab of T-DM1 can bind to the HER2 receptor of cancer cells and block the formation of a heterodimer between HER2 and HER1, HER3, or HER4, which inhibits the signal transduction pathways (like PI3K or MAPK) of cell survival and proliferation to induce the cell apoptosis.

In the early stage, ADC, such as BR96-doxorubicin, mainly consisted of a conventional chemotherapy drug conjugated to a mouse-derived antibody through a non-cleavable linker. The potency of those ADCs was not superior to free cytotoxic drugs and the immunogenicity was frequently a concern. Later on, the use of much more potent cytotoxic agents in a combination of humanized mAbs resulted in greatly improved efficacy and safety and thus market approval for the first-generation ADCs, including gemtuzumab ozogamicin and inotuzumab ozogamicin. In these two products, humanized mAbs of the IgG4 isotype were used and conjugated to the potent cytotoxic calicheamicin through the acid-labile linkers. The system is, however, not flawless.

Report Highlights

In January 2025, Vincerx Pharma, Inc and Oqory, Inc., highlighted Phase Ia/Ib data for Oqory’s anti-TROP2 ADC, OQY-3258, for patients with solid tumors. The companies also provided insights into their proposed strategic merger, which aims to advance OQY-3258 into global Phase III trials and build a differentiated ADC pipeline by leveraging their combined expertise.

In January 2025, Innate Pharma SA announced the first patient was dosed in its Phase I study (NCT06781983), investigating the safety and tolerability of IPH4502, an innovative Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4.

In January 2025, Zai Lab Limited announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of Small Cell Lung Cancer (SCLC).

In January 2025, Araris Biotech AG announced they have entered a Research Collaboration and Option to License Agreement (“RCO”) under which Araris will use its proprietary linker-conjugation platform, AraLinQ™, to generate novel ADCs using antibodies against undisclosed targets provided by Chugai Pharmaceutical Co., Ltd. (""Chugai"").

In January 2025, -Avenzo Therapeutics, Inc. and Duality Biotherapeutics announced that they have entered into an exclusive license agreement, pursuant to which Avenzo will develop, manufacture and commercialize AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC, globally (excluding Greater China).

In December 2024, -Gilead Sciences, Inc. and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target.

In December 2024, Duality Biologics announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324. Under the agreement, DualityBio will grant GSK an exclusive option to obtain a license to develop and commercialize DB-1324 worldwide (excluding mainland China, Hong Kong, and Macau) (the ""Option"").

In October 2024, Alentis Therapeutics announced that the U.S. Food & Drug Administration (FDA) cleared an IND application for ALE.P02, an anti-CLDN1 ADC with a tubulin inhibitor payload. A Phase I/II clinical trial in patients with CLDN1+ squamous tumors is expected to start during the first quarter of 2025.

In September 2024, Elevation Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy.

In September 2024, Innate Pharma SA announced that the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase I clinical study of IPH4502, its novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 in solid tumors. Innate expects to initiate the Phase 1 study in the coming months.

Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)

1. Company Overview: Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Product Description: Trodelvy

Trodelvy (sacituzumab govitecan-hziy) is a first-in-class Trop-2 directed antibody-drug conjugate. Trop-2 is a cell surface antigen highly expressed in multiple tumor types, including in more than 90% of breast and bladder cancers. Trodelvy is intentionally designed with a proprietary hydrolyzable linker attached to SN-38, a topoisomerase I inhibitor payload. This unique combination delivers potent activity to both Trop-2 expressing cells and the microenvironment. Trodelvy is approved in more than 40 countries, with multiple additional regulatory reviews underway worldwide, for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. Trodelvy is also approved in the U.S. to treat certain patients with pre-treated HR+/HER2- metastatic breast cancer and has an accelerated approval for treatment of certain patients with second-line metastatic urothelial cancer. Trodelvy is also being developed for potential investigational use in other TNBC, HR+/HER2- and metastatic UC populations, as well as a range of tumor types where Trop-2 is highly expressed, including metastatic non-small cell lung cancer (NSCLC), metastatic small cell lung cancer (SCLC), head and neck cancer, and endometrial cancer.

2. Company Overview: Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, the company has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Product Description: KADCYLA

KADCYLA is an antibody-drug conjugate engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1. KADCYLA is approved as a single agent in over 100 countries, including the US and EU, for the treatment of people with HER2-positive advanced breast cancer who have previously received Herceptin and taxane-based chemotherapy, either separately or in combination. KADCYLA is also approved in the US and EU for the adjuvant (post-surgery) treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant (pre-surgery) treatment that included Herceptin and taxane-based chemotherapy. KADCYLA (enfortumab vedotin-ejfv) is a first-in-class antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer. Nonclinical data suggest the anticancer activity of KADCYLA is due to its binding to Nectin-4-expressing cells, followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis).

Antibody Drug Conjugate: Company and Product Profiles (Pipeline Therapies)

1. Company Overview: Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need.

Product Description: Patritumab deruxtecan

Patritumab deruxtecan (HER3-DXd) is one of three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a fully human anti-HER3 IgG1 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Patritumab deruxtecan is currently being evaluated as both a monotherapy and in combination with other anticancer therapies. The development program includes HERTHENA-Lung01, a pivotal Phase II study in patients with locally advanced or metastatic EGFR-mutated NSCLC previously treated with a TKI and platinum-based chemotherapy; a Phase I/II study in HER3 expressing metastatic breast cancer; a Phase I study in combination with osimertinib in locally advanced/metastatic EGFR-mutated NSCLC; and, a Phase I study in previously treated patients with metastatic or unresectable NSCLC. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer. Currently, the drug is in Preregistration stage of its development for the treatment of Non-small cell lung cancer.

2. Company Overview: Company Overview: AbbVie

AbbVie Inc (AbbVie) is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.

Product Description: ABBV-399

ABBV-399 (telisotuzumab vedotin) is a first-in-class anti-c-Met antibody drug conjugate that targets both c-Met-amplified and c-Met-overexpressing tumors. It is currently being investigated to treat advanced solid tumors. c-Met expression is significantly higher in many solid tumors compared to normal tissue and is a marker of poor prognosis. ABBV-399 is an investigational compound and its safety and efficacy have not been evaluated by the FDA or any other health authority. Currently, the drug is in Preregistration stage of its development for the treatment of Non-small cell lung cancer.

3. Company Overview: Jiangsu HengRui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co Ltd (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.

Product Description: SHR-A1811

SHR-A1811 is an innovative HER2-targeted antibody-drug conjugate with a topoisomerase I payload conjugated to an anti-HER-2 mAb by a cleavable linker. Once bound to HER2 expressing tumor cells, the ADC is internalized and the linker releases the toxin, leading to tumor cell death. It can bind to the cell membrane surface of HER2 expressing cells, and then enter the cells to reach the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells. Preclinical research results show that SHR-A1811 has good anti-tumor activity, safety, tolerability and pharmacokinetic characteristics, or can further improve drug resistance, enhance efficacy, meet clinical needs, and provide more cancer patients multiple choice. Currently, the drug is in the Phase III stage of its development for the treatment of HER2 positive breast cancer.

4. Company Overview: Sutro Biopharma

Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, on MK-1484, a selective IL-2 agonist in clinical studies as a monotherapy and in combination with pembrolizumab for the treatment of solid tumors; and with Astellas Pharma (Astellas) on novel modality, immunostimulatory antibody-drug conjugates (iADCs).

Product Description: STRO-002

STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. STRO-002 was generated by conjugation of a novel cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to the nonnatural amino acid para-azidomethyl-L-phenylalanine incorporated at specific positions within a high affinity anti-FolRα antibody using Sutro's XpressCF+, which resulted in a homogeneous ADC with a drug–antibody ratio (DAR) of 4. STRO-002 binds to FolRα with high affinity, internalizes rapidly into target positive cells, and releases the tubulin-targeting cytotoxin 3-aminophenyl hemiasterlin (SC209). SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. IBI322 is currently being evaluated in Phase II/III for the treatment of Ovarian cancer.

5. Company Overview: Daiichi Sankyo Company

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need.

Product Description: DS-6000

DS-6000a is an antibody-drug conjugate, comprised of an humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I (TOP1) inhibitor payload via a cleavable linker. DS-6000a specifically binds to CDH6 on the surface of tumor cells and is internalized upon binding. The payload is then released, resulting in target cell apoptosis. In preclinical studies, DS-6000a inhibited tumor growth and induced tumor regression in CDH6-expressing RCC and OVC. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Ovarian cancer.

6. Company Overview: Chia Tai Tianqing Pharmaceutical Group

Chia Tai Tianqing Pharmaceutical Group is a multinational pharmaceutical company with integrated R&D, manufacturing, marketing, sales and distribution capabilities. It is the core enterprise of Sino Biopharmaceutical. With more than 14000 employees, CTTQ is well-known in the field of anti-tumor and liver disease in China. At present, the company manufactures over 50 prescription medicines in 5 core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics and diabetes. CTTQ has 2 R&D centers institutes with a total of over 1800 employees. They invest 10%-12% of annual sales revenue in R&D every year.

Product Description: TQB 2102

TQB 2102, is an investigational drug being developed by Chia Tai Tianqing Pharmaceutical Group. TQB 2102 acts as a DNA topoisomerase I inhibitors. It is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via an enzyme-cleavable linker, to a topoisomerase I (TopoI) inhibitor payload, with potential antineoplastic activity. Upon administration of the anti-HER2/topoisomerase I inhibitor ADC TQB2102, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the TopoI inhibitor inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication which results in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. TQB 2102 is currently being evaluated in Phase II for the treatment of HER2 negative breast cancer.

7. Company Overview: Company Overview: Mythic Therapeutics

Mythic Therapeutics is a product-platform company that is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. The company’s technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, the focus is on patient-centered science with the goal to leave a lasting impact on cancer care. The Company’s FateControl™ technology aims to enhance ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the diseases and patient profiles that could be treated with Mythic’s ADCs. The company’s major investors include Venrock, Viking Global Investors, and First Round Capital.

Product Description: MYTX-011

MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControl™ technology, which allows ADCs to actively navigate inside of cells to potentially increase delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles. MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent Antimicrotubule Drug Monomethyl Auristatin E (MMAE). The FDA has also granted Fast Track Designation to MYTX-011 for use as a potential therapeutic option in patients with non–small cell lung cancer (NSCLC) and cMET overexpression. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.

8. Company Overview: Company Overview: Oncomatryx Biopharma S.L.

Oncomatryx, a global biopharmaceutical company, is pioneering the development of precision ADCs and bispecific antibodies against novel targets in the tumor microenvironment. The company, located in the Bizkaia Technology Park (Bilbao, Spain), has discovered novel pathways and proteins in the Cancer-Associated Fibroblasts that surround the tumor and promote its invasiveness, immunosuppression and drug resistance. Oncomatryx has undertaken the development of pioneering drugs against these pathways and proteins of the tumor microenvironment, in collaboration with prestigious universities and hospitals in USA and Europe, led by the Institute of Cell Biology and Immunology of the University of Stuttgart (Germany).

Product Description: OMTX705

OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression. OMTX705 has already shown unbeatable safety in non-human primates and tumor regression in murine models of pancreatic, breast, lung and gastric cancer. Oncomatryx will run a multicenter, dose escalation trial in patients suffering metastatic solid tumors. OMTX705 will be administered as single agent and in combination with immunotherapy. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Advanced Solid Tumor.

Further product details are provided in the report……..

Antibody Drug Conjugate Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Antibody Drug Conjugate Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Antibody Drug Conjugate Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Antibody Drug Conjugate Report Assessment

Company Analysis

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Antibody Drug Conjugate drugs?

How many Antibody Drug Conjugate drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Antibody Drug Conjugate?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bispecific antibody therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Bispecific antibody and their status?

What are the key designations that have been granted to the emerging and approved drugs?

Key Players

Gilead Sciences, Inc

Roche

Daiichi Sankyo

AbbVie

Jiangsu HengRui Medicine Co., Ltd.

ProfoundBio

Sutro Biopharma

Chia Tai Tianqing Pharmaceutical Group

Heidelberg Pharma AG

Mythic Therapeutics

Oncomatryx Biopharma S.L.

Seagen

ImmunoGen

Pfizer

Iksuda Therapeutics

Oxford Therapeutics

Pyxis Oncology

Alteogen

Suzhou GeneQuantum Healthcare

Duality Biologics

LegoChem Biosciences

RemeGen

Sorrento Therapeutics, Inc.

LaNova Medicines Limited

OBI Pharma

Bio-Thera Solutions

BioAtla, Inc.

Ambrx

Lepu Biopharma

Klus Biopharma

Key Products

Trodelvy

KADCYLA

Patritumab deruxtecan

ABBV-399

SHR-A1811

PRO1184

STRO-002

TQB-2102

TLX-250

MYTX-001

OMTX705

Disitamab vedotin

ELAHERE

MYLOTARG

IKS03

OBT076

PYX 201

ALT-P7

GQ 1001

DB-1311

LCB84

RC 118

STI-6129

LM-305

OBI-999

BAT8006

BA-3021

ARX788

MRG 003

A166


Please Note: It will take 4-5 business days to complete the report upon order confirmation.